JP2023138660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023138660A5 JP2023138660A5 JP2023129040A JP2023129040A JP2023138660A5 JP 2023138660 A5 JP2023138660 A5 JP 2023138660A5 JP 2023129040 A JP2023129040 A JP 2023129040A JP 2023129040 A JP2023129040 A JP 2023129040A JP 2023138660 A5 JP2023138660 A5 JP 2023138660A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- recombinant
- population
- subject
- follistatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 143
- 238000000034 method Methods 0.000 claims description 72
- 108010014612 Follistatin Proteins 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 29
- 102000016970 Follistatin Human genes 0.000 claims description 19
- 240000007019 Oxalis corniculata Species 0.000 claims description 15
- 208000021642 Muscular disease Diseases 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 7
- 201000006938 muscular dystrophy Diseases 0.000 claims description 7
- 101000931668 Homo sapiens Follistatin Proteins 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 208000029578 Muscle disease Diseases 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 5
- 102000050536 human FST Human genes 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 3
- 210000003720 plasmablast Anatomy 0.000 claims description 3
- 210000004180 plasmocyte Anatomy 0.000 claims description 3
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 2
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 108020004414 DNA Proteins 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101100332578 Homo sapiens DHFR gene Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644362P | 2018-03-16 | 2018-03-16 | |
| US201862644356P | 2018-03-16 | 2018-03-16 | |
| US62/644,362 | 2018-03-16 | ||
| US62/644,356 | 2018-03-16 | ||
| PCT/US2019/022821 WO2019178613A1 (en) | 2018-03-16 | 2019-03-18 | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| JP2020548962A JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548962A Division JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023138660A JP2023138660A (ja) | 2023-10-02 |
| JP2023138660A5 true JP2023138660A5 (enExample) | 2025-03-03 |
Family
ID=65995892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548962A Pending JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
| JP2023129040A Pending JP2023138660A (ja) | 2018-03-16 | 2023-08-08 | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548962A Pending JP2021515576A (ja) | 2018-03-16 | 2019-03-18 | フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210047619A1 (enExample) |
| EP (1) | EP3765601A1 (enExample) |
| JP (2) | JP2021515576A (enExample) |
| CN (1) | CN111936617A (enExample) |
| AU (2) | AU2019233929B2 (enExample) |
| CA (1) | CA3093716A1 (enExample) |
| WO (1) | WO2019178613A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971039B1 (en) | 2013-03-14 | 2020-01-01 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
| CN110709090A (zh) * | 2017-04-27 | 2020-01-17 | 益缪索夫特公司 | 用于在体内递送治疗剂的b细胞及其剂量 |
| CN113677354A (zh) * | 2019-01-23 | 2021-11-19 | 综合医院公司 | B细胞免疫疗法 |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| WO2025047766A1 (ja) * | 2023-08-29 | 2025-03-06 | 富士フイルム株式会社 | ウイルスの製造方法および細胞への核酸導入方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5124259A (en) | 1989-08-23 | 1992-06-23 | Mitsui Toatsu Chemicals, Inc. | Method for electroporation |
| DE4223128C2 (de) | 1991-07-15 | 1995-06-14 | Handtmann Albert Maschf | Verfahren und Vorrichtung zum Vereinzeln und Aufbringen einer Darmraupe auf ein Füllrohr |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| DE69433970T2 (de) | 1993-08-10 | 2005-08-11 | W.L. Gore & Associates, Inc., Newark | Zelleinkapselungsvorrichtung |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| EP0773753B1 (en) | 1995-06-07 | 2003-10-08 | Gore Hybrid Technologies, Inc. | An implantable containment apparatus for a therapeutical device |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1369108A4 (en) | 2001-02-19 | 2007-06-20 | Pola Chem Ind Inc | COMPOSITION FOR USE IN ELECTROPORATION |
| WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| CN1929734A (zh) * | 2002-02-21 | 2007-03-14 | 惠氏公司 | 含卵泡抑素区的蛋白质 |
| US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| JP2006502748A (ja) | 2002-09-05 | 2006-01-26 | カリフォルニア インスティテュート オブ テクノロジー | 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法 |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CN1993146A (zh) * | 2004-06-01 | 2007-07-04 | 健泰科生物技术公司 | 抗体－药物偶联物和方法 |
| AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| WO2007014275A2 (en) | 2005-07-26 | 2007-02-01 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| ES2626025T3 (es) | 2005-10-18 | 2017-07-21 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| US7799555B2 (en) | 2006-02-10 | 2010-09-21 | Bio-Rad Laboratories, Inc. | Apparatus for high-throughput electroporation |
| AU2008317354B2 (en) | 2007-10-25 | 2014-04-10 | Ospedale San Raffaele S.R.L. | Methods and compositions for targeted integration |
| US8551780B2 (en) | 2008-02-01 | 2013-10-08 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Electroporation buffer composition and method of use |
| WO2009131632A1 (en) | 2008-04-14 | 2009-10-29 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| KR20160015400A (ko) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
| EP2358868B1 (en) | 2008-11-21 | 2014-11-12 | California Institute of Technology | In vitro human b lymphopoiesis culture system |
| WO2011085247A2 (en) | 2010-01-08 | 2011-07-14 | Immusoft Corporation | Vectors and methods for transducing b cells |
| WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| KR101637933B1 (ko) | 2010-03-15 | 2016-07-08 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 포유동물 세포로의 유전자 도입효율의 향상제 |
| CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| CN107982548A (zh) * | 2012-02-07 | 2018-05-04 | 全球生物疗法有限公司 | 核酸输送的区室化方法及其组合物和应用 |
| JP6475639B2 (ja) * | 2013-01-25 | 2019-02-27 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
| EP2971039B1 (en) | 2013-03-14 | 2020-01-01 | Immusoft Corporation | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors |
| SG11201608393TA (en) * | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| WO2015187977A1 (en) * | 2014-06-04 | 2015-12-10 | Acceleron Pharma, Inc. | Methods and compositions for treatment of disorders with follistatin polypeptides |
| US10010498B2 (en) * | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| WO2016057975A2 (en) * | 2014-10-10 | 2016-04-14 | Research Institute At Nationwide Children's Hospital | Guided injections for aav gene transfer to muscle |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| JP6734283B2 (ja) * | 2015-01-21 | 2020-08-05 | フレッド ハッチンソン キャンサー リサーチ センター | 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム |
| EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| JP7146632B2 (ja) * | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
-
2019
- 2019-03-18 JP JP2020548962A patent/JP2021515576A/ja active Pending
- 2019-03-18 WO PCT/US2019/022821 patent/WO2019178613A1/en not_active Ceased
- 2019-03-18 CA CA3093716A patent/CA3093716A1/en active Pending
- 2019-03-18 CN CN201980019277.XA patent/CN111936617A/zh active Pending
- 2019-03-18 US US16/981,618 patent/US20210047619A1/en active Pending
- 2019-03-18 EP EP19714953.7A patent/EP3765601A1/en active Pending
- 2019-03-18 AU AU2019233929A patent/AU2019233929B2/en active Active
-
2023
- 2023-08-08 JP JP2023129040A patent/JP2023138660A/ja active Pending
-
2025
- 2025-08-29 AU AU2025223865A patent/AU2025223865A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023138660A5 (enExample) | ||
| JP7490704B2 (ja) | 遺伝子組換えにより内在性ｆｏｘｐ３遺伝子の発現が安定化されたｃｄ４ ｔ細胞を使用した自己免疫疾患の治療方法 | |
| JP2021507703A (ja) | Ｖｃａｒ組成物とその利用法 | |
| JP2019500043A5 (enExample) | ||
| CN111690050B (zh) | 识别ebv-lmp2抗原的tcr及相应的核酸分子、载体、细胞和药物 | |
| US12030922B2 (en) | IL-31 improves efficacy of macrophage-based adoptive cell therapy for cancer | |
| AU2022213505A1 (en) | Gene silencing | |
| JP2020517692A5 (enExample) | ||
| CN115552019A (zh) | 在髓样细胞和小胶质细胞中特异性表达治疗性蛋白的病毒载体 | |
| US20220127575A1 (en) | Genetically modified hematopoietic stem and progenitor cells (hspcs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches | |
| CA2549394A1 (en) | Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and uses thereof | |
| JPWO2019178613A5 (enExample) | ||
| CN111499766A (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| JP2025528163A (ja) | キメラｃｄ８－アルファ補助受容体組成物及び使用方法 | |
| EP3635098B1 (en) | T-cells modified to overexpress phf19 | |
| Ansorge et al. | Towards continuous bioprocessing of lentiviral vectors | |
| RU2020133851A (ru) | B-клетки, генетически модифицированные для секреции фоллистатина, и способы их применения для лечения связанных с фоллистатином заболеваний, состояний, нарушений и для увеличения роста и силы мышц | |
| Baumeister et al. | Gene and Cell Therapy: How to Build a BioDrug | |
| WO2025221789A1 (en) | Compositions and methods for use in car/tcr cell therapies | |
| WO2025072717A1 (en) | Treating cancer | |
| CN119799717A (zh) | 核酸形式il-9联合免疫检查点药物的制剂组合与应用 | |
| CN120098141A (zh) | 一种通用型抗肿瘤的SynNotch合成受体组合及其应用 | |
| Houghton et al. | 325. Targeted Gene Addition Strategies for the Treatment of X-Linked Lymphoproliferative Disease | |
| HK40013246A (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene |